Cobas Integra: clinical laboratory instrument with continuous and random-access capabilities

Area of Science:

• Clinical Laboratory Diagnostics
• Analytical Chemistry
• Biomedical Engineering

Background:

• The clinical laboratory landscape demands efficient and versatile analytical systems.
• Continuous and random-access analyzers are crucial for managing diverse testing needs.
• The Cobas Integra by Roche Diagnostic Systems is introduced as a novel solution.

Purpose of the Study:

• To evaluate the performance characteristics of the Cobas Integra clinical laboratory analyzer.
• To assess its capabilities for routine chemistries, specific proteins, electrolytes, hormones, and drug testing.
• To compare its analytical performance against established systems.

Main Methods:

• Description of the analyzer's configuration, including subsystems for absorbance, fluorescence polarization, and ion-selective electrode (ISE) measurements.
• Evaluation of performance metrics such as precision, methods comparison, and on-board reagent stability.
• Testing of 29 assays across various analyte groups.

Main Results:

• Good agreement (r > or = 0.98) was observed when comparing Cobas Integra assays to established methods on Olympus, Hitachi, Behring, and Abbott systems.
• Total assay precision (CV) ranged from 0.8% to 8.5%.
• Calibration curves showed stability for up to 20 weeks, with test throughput up to 750 tests/hour (including ISE).

Conclusions:

• The Cobas Integra analyzer demonstrates robust performance, high precision, and excellent on-board stability.
• Its broad analytical capabilities and high throughput make it a valuable tool for clinical laboratories.
• The system offers reliable results comparable to existing gold-standard platforms.